Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2

NCT04604470 is registered in ClinicalTrials.gov with Maastricht University as lead sponsor.

NCT NCT04604470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04604470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Lead sponsor
Maastricht University
Phase
Observational
Overall status
Unknown status
Start date
October 20, 2020
Completion date
December 31, 2023
Enrollment
126 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, metastatic cancer, non small cell lung cancer, nsclc stage iv